Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases.Leveraging our novel allogeneic EBV T-cell platform, Atara intends to deliver treatments to patients with high unmet medical need. Our platform aims to leverage the unique biology of EBV T cells to channel the power of the immune system and has the potential to treat a wide range of diseases. Atara is applying this one platform to create a robust pipeline with the goal of developing treatments that improve the quality and longevity of patients' lives.
Funding Rounds 2
|17.12.2013||Series B||$38.5M||-||Atara Biot...|
Mentions in press and media 6